The Egyptian Pharmacovigilance Center (EPVC) Newsletter, January 2026 edition, presents critical safety information for healthcare professionals, including a significant label update regarding mesalazine and idiopathic intracranial hypertension, a detailed local case report on warfarin-food interaction leading to ischemic stroke, and a comprehensive summary of the center’s 2025 achievements.
Section 1: Label Update – Mesalazine and Idiopathic Intracranial Hypertension
1.1 Background and Regulatory Context
The UK regulatory authority (MHRA) published a significant label update regarding mesalazine, which has been adopted by the Egyptian Drug Authority (EDA). The key message is that idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine . Following a recent review, warnings for IIH are being added to the product information for all mesalazine-containing products in Egypt .
1.2 What is Mesalazine?
Mesalazine (also known as mesalamine or 5-aminosalicylic acid) is an aminosalicylate anti-inflammatory drug licensed for the treatment of inflammatory bowel disease (IBD), including:
| Condition | Description |
|---|---|
| Ulcerative Colitis | Chronic inflammatory condition affecting the colon |
| Crohn’s Disease | Inflammatory bowel disease that can affect any part of the gastrointestinal tract |
Mesalazine works locally in the gut to reduce inflammation, but systemic absorption can occur, leading to potential adverse effects in other organ systems .
1.3 What is Idiopathic Intracranial Hypertension (IIH)?
IIH is a condition characterized by increased pressure within the skull (intracranial pressure) without an identifiable cause (hence “idiopathic”). It is sometimes referred to as pseudotumor cerebri.
1.3.1 Clinical Presentation
The majority of patients presenting with IIH experience a combination of symptoms. It is important to note that none of these symptoms alone are unique to IIH :
| Symptom Category | Specific Manifestations |
|---|---|
| Headache | Progressively more severe and frequent; highly variable in type |
| Visual Disturbances | Transient visual obscurations (unilateral or bilateral vision darkening lasting seconds); visual blurring; typically horizontal diplopia (double vision) |
| Auditory Symptoms | Pulsatile tinnitus (ringing or buzzing in ears synchronous with heartbeat) |
| Pain | Back pain, neck pain, radicular pain |
| Neurological | Dizziness, cognitive disturbances |
1.3.2 Diagnosis
Diagnosis of IIH typically involves:
- Blood pressure monitoring – to rule out hypertensive emergencies
- Ophthalmology examination – including fundoscopy to assess for papilledema (swelling of the optic disc)
- Brain imaging (CT/MRI) – to exclude structural causes of increased intracranial pressure
- Lumbar puncture – to measure opening pressure and analyze cerebrospinal fluid
Where diagnostic uncertainty remains, experienced clinicians (neurology, neurosurgery, ophthalmology) should be consulted .
1.4 Risk-Benefit Analysis
The number of reported IIH cases associated with mesalazine is very low in the UK and globally. However, given the potentially serious consequences of untreated IIH—including permanent vision loss—regulatory action is warranted.
1.5 Updated Product Information in Egypt
The Summary of Product Characteristics (SmPC) for all mesalazine-containing products in Egypt will be updated to include a warning about the risk of IIH .
1.6 Recommendations for Healthcare Professionals
| Recommendation | Action |
|---|---|
| Patient Education | Warn patients using any form of mesalazine to look for signs and symptoms of IIH including severe or recurrent headache, visual disturbances, or tinnitus |
| Clinical Vigilance | Remain vigilant for signs and symptoms of IIH in patients taking mesalazine |
| Multidisciplinary Approach | Act promptly with a multidisciplinary approach, involving clinicians managing the patient’s IBD as well as neurology, neurosurgery, and ophthalmology teams as appropriate |
| Management of Symptoms | If symptoms of IIH occur, consider discontinuation of mesalazine and begin immediate management of symptoms |
| Pre-existing Conditions | Exercise caution when prescribing mesalazine to patients with previously diagnosed or suspected IIH |
1.7 Advice for Healthcare Professionals to Provide to Patients
| Key Message | Explanation |
|---|---|
| Risk Awareness | There have been very rare reports of increased pressure within your skull (idiopathic intracranial hypertension or IIH) in some patients receiving mesalazine |
| Prognosis | IIH is not normally life-threatening; however, in rare cases can cause serious vision problems which must be monitored and treated where possible |
| When to Seek Help | Tell your doctor immediately if you experience progressively more severe and recurrent headache, disturbed vision, ringing or buzzing in the ears, back pain, dizziness, or neck pain |
Section 2: Local Case Safety Report – Warfarin and Leafy Greens Interaction Leading to Ischemic Stroke
2.1 Case Summary
In September 2025, the Regional Center of Pharmacovigilance in Cairo received a critical report highlighting a preventable adverse event :
| Parameter | Details |
|---|---|
| Patient | 39-year-old male |
| Medical History | Coronary Artery Bypass Graft (CABG) and aortic valve replacement (5 years prior) |
| Medication | Oral warfarin 3 mg once daily (maintained) |
| Incident | Consumed large amount of green vegetables and liver |
| Outcome | Developed ischemic stroke on 8 September 2025, requiring hospitalization |
| Management | Aspirin administered; warfarin dose increased from 3 mg to 5 mg |
| Recovery | Patient subsequently recovered |
2.2 Background: Warfarin Pharmacology
Warfarin is an anticoagulant medication that works by decreasing the clotting ability of the blood. It is primarily used for :
| Indication | Description |
|---|---|
| Coronary occlusion | Prevention of further clotting after heart attack |
| Deep vein thrombosis (DVT) | Treatment and prevention of blood clots in deep veins |
| Pulmonary embolism | Treatment of blood clots in lungs |
| Peripheral vascular thromboembolism | Clots in peripheral arteries/veins |
| Mesenteric thromboembolism | Clots in intestinal blood vessels |
| Retinal thromboembolism | Clots in retinal vessels |
2.2.1 Mechanism of Action
Warfarin is a synthetic 4-hydroxycoumarin derivative that acts by preventing the formation of active procoagulation factors II, VII, IX, and X in the liver. It does this by inhibiting the vitamin K-mediated gamma-carboxylation of precursor proteins .
Key Points:
- Full therapeutic activity is not achieved until circulating coagulation factors have been removed by normal catabolism
- Factor VII has the shortest half-life, so its levels drop first
- Warfarin has no direct thrombolytic effect but may limit the extension of existing thrombi
2.2.2 Warfarin Dosing
| Population | Dosing Recommendations |
|---|---|
| Adults | 10–15 mg daily, adjusted based on INR; maintenance dose determined by regular monitoring |
| Children | Infants, especially neonates, may be more sensitive due to vitamin K deficiency |
| Elderly | May be more susceptible to effects; lower maintenance doses may be required |
2.3 The Vitamin K-Warfarin Interaction
2.3.1 Mechanism of Interaction
Vitamin K is an essential cofactor for the hepatic synthesis of vitamin K-dependent clotting factors (II, VII, IX, and X). Green leafy vegetables (such as spinach, broccoli, cabbage, kale, and lettuce) and liver are rich in vitamin K .
The Antagonistic Effect:
| Factor | Effect |
|---|---|
| High dietary vitamin K intake | Antagonizes warfarin’s anticoagulant effect |
| Mechanism | Vitamin K reduces warfarin’s ability to inhibit vitamin K epoxide reductase |
| Result | Subtherapeutic anticoagulation (reduced INR) |
| Clinical Consequence | Increased risk of thromboembolic events (e.g., ischemic stroke) |
2.3.2 Why This Case is Clinically Significant
In this patient:
- Underlying cardiovascular risk factors (post-CABG, mechanical valve)
- Sudden, excessive increase in vitamin K-rich food intake
- Resulted in subtherapeutic anticoagulation
- Led to ischemic stroke—a preventable catastrophic event
The Critical Message: Consistent and excessive fluctuations in vitamin K intake have been associated with poor warfarin control and increased variability in anticoagulant response .
2.4 Recommendations for Healthcare Professionals
The EPVC newsletter provides comprehensive recommendations for healthcare professionals managing patients on warfarin :
| Recommendation Category | Specific Actions |
|---|---|
| Monitoring | Educate patients on regular INR monitoring; maintain therapeutic range to prevent complications |
| Dietary Counseling | Advise maintaining a consistent diet, especially regarding vitamin K intake; warn patients to consume green leafy vegetables and liver with caution |
| Drug Interaction Screening | Screen for potential drug interactions before prescribing warfarin, including OTC medications, herbal supplements, and other anticoagulants |
| Concomitant Medications | Counsel patients to avoid aspirin, NSAIDs, and other blood-thinning agents unless specifically prescribed |
| Lifestyle Modifications | Recommend limiting alcohol intake and avoiding binge drinking; instruct on measures to minimize bleeding risk (soft toothbrush, avoid contact sports) |
| Communication | Encourage patients to inform all healthcare providers about warfarin therapy before any surgical or dental procedures |
| Adverse Event Monitoring | Monitor for and immediately address signs of bleeding or thrombosis (unusual bruising, hematuria, stroke symptoms) |
| Documentation | Document all dose adjustments, dietary changes, and adverse events; ensure timely follow-up |
| Personalized Dosing | Consider personalized dosing based on age, comorbidities, genetic factors, and concomitant medications |
| Specialist Coordination | Coordinate with specialist services (hematology, cardiology) in complex cases or if anticoagulation control proves difficult |
2.5 Patient Education Points
| Topic | Key Message |
|---|---|
| Dietary Consistency | Keep your overall diet stable and avoid sudden big changes in what you eat |
| Vitamin K-Rich Foods | Green vegetables (spinach, broccoli, cabbage, kale, lettuce) and liver contain vitamin K that can affect your warfarin |
| Monitoring | Regular INR testing is essential to ensure your blood is thin enough to prevent clots but not too thin to cause bleeding |
| When to Seek Help | Report any unusual bleeding, bruising, or symptoms of stroke (sudden weakness, difficulty speaking, vision changes) immediately |
Section 3: EPVC 2025 Highlights – A Year Worth Celebrating
The Egyptian Pharmacovigilance Center’s newsletter also provides a comprehensive summary of achievements in 2025, demonstrating significant progress in pharmacovigilance capacity building and patient safety initiatives .
3.1 Strategic Initiatives
3.1.1 “Be Vigilant” Initiative
Launched in June 2025, the Be Vigilant initiative was designed under the slogan “Expand the Learning More” to:
- Increase adverse drug reaction (ADR) reporting
- Maximize the capacity of central pharmacovigilance focal points within hospitals
- Target hospitals across diverse affiliations including:
- SMC (Specialized Medical Centers)
- GOTH (General Organization of Teaching Hospitals)
- SCOUH (Supreme Council of University Hospitals)
The program successfully trained one cohort at both beginner and intermediate levels .
3.2 International Representation
EPVC actively represented Egypt in 5 major international conferences and training programs, strengthening international collaboration and positioning Egypt as a leader in global pharmacovigilance .
3.3 Awareness and Educational Visits
| Target Audience | Number Reached |
|---|---|
| Academic staff members and students (faculties of pharmacy) | 200 |
| Healthcare professionals within private hospitals | 247 |
These visits promoted the importance of pharmacovigilance systems and their integration within the healthcare ecosystem .
3.4 National Scientific Events Participation
| Event Type | Impact |
|---|---|
| Major scientific conferences | Approximately 300 HCPs, hospital directors, and health sector decision makers |
| Career fairs (Cairo University, Ain Shams University) | Nearly 1100 students across different academic stages |
3.5 Trainings and Workshops
Capacity building remained a central pillar of EPVC’s strategy through:
| Training Type | Statistics |
|---|---|
| Physical and virtual lectures/webinars | 71 sessions |
| Healthcare professionals reached | 4,189 |
These activities reinforced standardized practices and fostered a culture of safety monitoring nationwide .
3.6 Impact on ICSR Reporting
As a direct result of these integrated efforts, EPVC achieved a remarkable increase in the number of Individual Case Safety Reports (ICSRs) . This milestone reflects:
- Improved reporting culture among healthcare professionals
- Strengthened operational efficiency
- Enhanced commitment to signal detection and patient safety
Section 4: EPVC Safety Tips – Food and Medicine Interactions
The newsletter includes practical safety tips for patients regarding food-drug interactions :
| Safety Tip | Explanation |
|---|---|
| Grapefruit Warning | Avoid grapefruit or grapefruit juice unless your doctor says it is safe (can affect many medications) |
| Dairy Products | Milk and dairy products may reduce the effect of some antibiotics |
| Green Vegetables (Warfarin) | Eat similar amounts of green vegetables if you take blood thinners like warfarin |
| Herbal Products | Tell your doctor or pharmacist about herbal products and supplements you use |
| Timing Instructions | Take your medicine with or without food exactly as instructed |
| Report Symptoms | Report any unusual symptoms after taking medicine with food or drinks |
Section 5: The Importance of ADR Reporting
5.1 Why Your Report Matters
The EPVC newsletter emphasizes that every report submitted counts when it comes to the safety of medicines and patients worldwide .
5.2 How to Report in Egypt
Healthcare professionals and patients can report adverse drug reactions to the Egyptian Drug Authority (EDA) through multiple channels :
| Method | Contact Information |
|---|---|
| pv.followup@edaegypt.gov.eg | |
| Hotline | 15301 |
| Website | EDA website |
| Alternative | Report through your pharmacy, product distributor, or company hotline—they are required to forward it to EDA |
5.3 Additional Resources
| Resource | Access |
|---|---|
| EDA website | All medicine-related news, updates, and alerts |
| EPVC Newsletters and DHPCs | Available on EDA website |
| Alerts regarding counterfeit/falsified products | Released by Central Administration of Operations |
Section 6: What is the Egyptian Pharmaceutical Vigilance Center?
The Egyptian Pharmaceutical Vigilance Center (EPVC) was established to be responsible for the safety monitoring of pharmaceutical products throughout their lifecycle. It is the regulatory authority regarding pharmacovigilance and its applications in Egypt .
6.1 Scope of Monitoring
EPVC monitors the safety of all types of pharmaceutical products, including :
| Category | Examples |
|---|---|
| Human medicines | Prescription and OTC drugs |
| Biological products | Vaccines, blood products, biotechnological products |
| Supplements | Vitamins, minerals, herbal supplements |
| Cosmetics | Skin care, hair care products |
| Veterinary medicines | Animal health products |
| Medical devices | All classes of medical devices |
| Biocides and pesticides | Disinfectants, pest control products |
6.2 Mission
The Pharmaceutical Vigilance administration is the way through which the processes for authorizing, requiring, monitoring, and evaluating the safety of any pharmaceutical product or medical device take place, in addition to disseminating any safety information for public health programs, healthcare professionals, and the Egyptian citizen .
6.3 Vision
The Pharmaceutical Vigilance administration is an integral part of the Central Administration of Pharmaceutical Care that works on the enhancement of pharmaceutical services to guarantee safe and effective use of medications in Egypt, under the patronage of the Egyptian Drug Authority .
Section 7: Call for Participation
EPVC invites healthcare professionals and the public to participate in a quick survey on how effective their communication is. The feedback is crucial in ensuring EPVC meets stakeholder expectations .
| Item | Details |
|---|---|
| Survey Purpose | Assess effectiveness of EPVC communication |
| Survey Link | EDA website |
| Value | Your insights help us enhance our communication |
Section 8: Clinical Takeaways and Conclusions
8.1 Key Messages from This Issue
| Topic | Takeaway |
|---|---|
| Mesalazine and IIH | Be vigilant for symptoms of idiopathic intracranial hypertension in patients on mesalazine; educate patients to report headaches, visual disturbances, or tinnitus |
| Warfarin and Diet | Sudden increases in vitamin K-rich foods can antagonize warfarin, leading to subtherapeutic INR and thromboembolic events; emphasize dietary consistency |
| Food-Drug Interactions | Always consider food-drug interactions in unexplained therapeutic failures or adverse events |
| Reporting Culture | Every ADR report matters; Egypt’s reporting system is accessible and impactful |
| EPVC Achievements | Egypt is making significant strides in pharmacovigilance capacity building and international collaboration |
8.2 The Role of Healthcare Professionals
Healthcare professionals are the frontline of pharmacovigilance. By:
- Staying informed about label updates and safety alerts
- Educating patients about medication risks and food interactions
- Maintaining vigilance for adverse events
- Reporting promptly to EPVC
We collectively contribute to safer medication use for all Egyptians and patients worldwide.
